Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • Working Paper

Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S.

By: Pragya Kakani, Michael Chernew and Amitabh Chandra
  • Format:Print
  • | Language:English
ShareBar

Abstract

Rising list prices are often used to illustrate the burden of prescription drug spending, but payers routinely negotiate rebates from manufacturers that generate differences between list and net prices. List prices are easily available and affect patient cost-sharing, but net prices are confidential and affect innovation incentives. We use novel data on medicines sold in a retail setting to quantify rebate growth, the sensitivity of pharmaceutical price indices to list versus net prices, and contribution of net price growth to revenue growth. From 2012 to 2017, we find average rebates increased from 32% to 48%, owing entirely to growth in rebate-levels over a product lifetime rather than shifts towards high rebate products. Annual inflation of list prices was 12% while that of net prices was 3%, implying that financial rewards to manufacturers per unit sold have not grown proportionally to list prices. This pattern is mirrored in 19 of the 20 top drug classes by revenue including insulins, where list and net price inflation were 16% and 2% annually respectively. Finally, we find price growth explains 76% of revenue growth when measured by list prices but 31% of revenue growth when measured by net prices. Moreover, new product entry is the most important factor affecting pharmaceutical revenue growth. These findings provide a cautionary note on using list prices for policy analysis.

Keywords

Pharmaceuticals; Rebates; Health Care and Treatment; Markets; Price; Analysis; Pharmaceutical Industry

Citation

Kakani, Pragya, Michael Chernew, and Amitabh Chandra. "Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S." NBER Working Paper Series, No. 26846, March 2020.
  • Find it at Harvard
  • Read Now

About The Author

Amitabh Chandra

Technology and Operations Management
→More Publications

More from the Authors

    • 2025
    • Faculty Research

    Expert Patients’ Use of Avoidable Health Care

    By: Amitabh Chandra, Pragya Kakani and Simone Matecna
    • November 2024
    • Quarterly Journal of Economics

    The Health Costs of Cost Sharing

    By: Amitabh Chandra, Evan Flack and Ziad Obermeyer
    • October 2024
    • Health Affairs

    Medicare Part D Protected-Class Policy Is Associated with Lower Drug Rebates

    By: Pragya Kakani, Michael Anne Kyle, Amitabh Chandra and Luca Maini
More from the Authors
  • Expert Patients’ Use of Avoidable Health Care By: Amitabh Chandra, Pragya Kakani and Simone Matecna
  • The Health Costs of Cost Sharing By: Amitabh Chandra, Evan Flack and Ziad Obermeyer
  • Medicare Part D Protected-Class Policy Is Associated with Lower Drug Rebates By: Pragya Kakani, Michael Anne Kyle, Amitabh Chandra and Luca Maini
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.